Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
about
Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@en
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@nl
type
label
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@en
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@nl
prefLabel
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@en
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@nl
P2093
P356
P1476
Corrigendum: Canagliflozin, da ...... eview and economic evaluation.
@en
P2093
Andrew Clegg
Bee Kang Tan
Christine Clar
David McGrane
Ewen Cummins
J Paul O'Hare
Jill Colquitt
Norman Waugh
Pamela Royle
Rachel Court
P304
P356
10.3310/HTA21020-C201802
P577
2018-02-01T00:00:00Z